Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Geron Corp (GERN)

Geron Corp (GERN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,076,712
  • Shares Outstanding, K 640,900
  • Annual Sales, $ 183,880 K
  • Annual Income, $ -83,500 K
  • EBIT $ -52 M
  • EBITDA $ -56 M
  • 60-Month Beta 0.67
  • Price/Sales 5.89
  • Price/Cash Flow N/A
  • Price/Book 4.78

Options Overview Details

View History
  • Implied Volatility 90.26% (-1.97%)
  • Historical Volatility 69.80%
  • IV Percentile 12%
  • IV Rank 6.86%
  • IV High 429.98% on 10/10/25
  • IV Low 65.22% on 06/04/25
  • Expected Move (DTE 25) 0.2550 (16.35%)
  • Put/Call Vol Ratio 0.22
  • Today's Volume 1,037
  • Volume Avg (30-Day) 720
  • Put/Call OI Ratio 0.44
  • Today's Open Interest 48,446
  • Open Int (30-Day) 53,591
  • Expected Range 1.3050 to 1.8150

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.03
  • Number of Estimates 4
  • High Estimate $-0.02
  • Low Estimate $-0.03
  • Prior Year $-0.03
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3800 +13.04%
on 03/30/26
1.8399 -15.21%
on 04/07/26
+0.1000 (+6.85%)
since 03/20/26
3-Month
1.2900 +20.93%
on 01/29/26
2.0100 -22.39%
on 02/19/26
+0.2600 (+20.00%)
since 01/20/26
52-Week
1.0400 +50.00%
on 11/07/25
2.0100 -22.39%
on 02/19/26
+0.2900 (+22.83%)
since 04/17/25

Most Recent Stories

More News
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective April 17, 2026, it granted stock...

GERN : 1.5600 (-7.14%)
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it granted an equity award in the form of a...

GERN : 1.5600 (-7.14%)
Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary

FOSTER CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today...

GERN : 1.5600 (-7.14%)
Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference

FOSTER CITY, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today...

GERN : 1.5600 (-7.14%)
Geron Announces Appointment of New Members to its Board of Directors

FOSTER CITY, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today...

GERN : 1.5600 (-7.14%)
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective March 17, 2026, it granted stock...

GERN : 1.5600 (-7.14%)
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:NTLA),(NASDAQ:NAGE),(NASDAQ:OCGN) EQNX::TICKER_END

AVAI : 0.3048 (-3.48%)
NAGE : 4.87 (+0.62%)
GERN : 1.5600 (-7.14%)
NTLA : 15.21 (+1.74%)
OCGN : 1.8500 (-7.04%)
Geron: Q4 Earnings Snapshot

Geron: Q4 Earnings Snapshot

GERN : 1.5600 (-7.14%)
Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Achieved $48 million and $184 million in RYTELO ® (imetelstat) net product revenue in Q4 2025 and full year 2025, respectively Reported total operating expenses of $255 million for full year 2025,...

GERN : 1.5600 (-7.14%)
Geron Plans to Present at Upcoming Investor Conferences

FOSTER CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today...

GERN : 1.5600 (-7.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic...

See More

Key Turning Points

3rd Resistance Point 1.7882
2nd Resistance Point 1.7385
1st Resistance Point 1.6493
Last Price 1.5600
1st Support Level 1.5104
2nd Support Level 1.4607
3rd Support Level 1.3715

See More

52-Week High 2.0100
Fibonacci 61.8% 1.6395
Last Price 1.5600
Fibonacci 50% 1.5250
Fibonacci 38.2% 1.4105
52-Week Low 1.0400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.